Trial Profile
A study to evaluate the efficacy of omalizumab for the treatment of aspirin-exacerbated respiratory disease (AERD)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 22 Apr 2021
Price :
$35
*
At a glance
- Drugs Omalizumab (Primary)
- Indications Allergic asthma
- Focus Adverse reactions; Therapeutic Use
- 01 Mar 2021 Results presented at the 2021 Annual Meeting of the American Academy of Allergy, Asthma and Immunology
- 16 Mar 2016 New trial record
- 07 Mar 2016 Results presented at the 2016 Annual Meeting of the American Academy of Allergy, Asthma and Immunology